A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
DENTSPLY SIRONA Inc.
XRAY
$2.6B
Mkt Cap
$12.93
+1.65%
DENTSPLY SIRONA Inc. (XRAY) has a 5-year average return on invested capital (ROIC) of -9.9%. This is below average and may indicate limited pricing power.
DENTSPLY SIRONA Inc. (XRAY) has a market capitalization of $2.6B. It is classified as a mid-cap stock.
Yes, DENTSPLY SIRONA Inc. (XRAY) pays a dividend with a trailing twelve-month yield of 4.94%.
DENTSPLY SIRONA Inc. (XRAY) operates in the Dental Equipment & Supplies industry, within the Healthcare sector.
DENTSPLY SIRONA Inc. (XRAY) reported annual revenue of $3.7 billion in its most recent fiscal year, based on SEC EDGAR filings.
DENTSPLY SIRONA Inc. (XRAY) has a net profit margin of -16.3%. The company is currently unprofitable.
DENTSPLY SIRONA Inc. (XRAY) generated $104 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with a 139-year history serving the dental industry globally. The company develops, manufactures, and markets comprehensive solutions across four reportable segments: Connected Technology Solutions (dental equipment, imaging systems, and CAD/CAM products), Essential Dental Solutions (endodontic, restorative, and preventative products), Orthodontic and Implant Solutions (dental implants and clear aligners), and Wellspect Healthcare (healthcare consumable products for urological and enterological applications). The company operates through a global distribution network, selling products in approximately 140 countries with significant market presence in the United States, Europe (particularly Germany, Sweden, France, the United Kingdom, Italy, and Switzerland), Asia-Pacific, Central and South America, the Middle East, and Canada. Dentsply Sirona's business model centers on providing integrated digital workflows and cloud-enabled software solutions (including the DS Core platform) alongside physical products, enabling dental practitioners to leverage technological advancements throughout patient care. The company's competitive positioning is built on a strong portfolio of world-class brands, comprehensive product offerings that serve as a one-stop shop for practitioners, and its ability to bundle solutions across segments to drive customer value and operational leverage.
【Return-to-Growth execution underway】 Management is executing a multi-year Return-to-Growth action plan focused on improving speed, accountability, and customer-centricity, with early momentum evident in commercial restructuring, clinical education expansion, and sales force training. The company is pursuing operational efficiencies through manufacturing and distribution network consolidation, standardized packaging, and advanced planning capabilities to unlock approximately $120 million annually in cost savings to be reinvested in innovation, clinical education, and commercial investments. Management expects more material benefits from these initiatives to emerge in the second half of 2026 and into 2027 and 2028, with positive sequential sales momentum anticipated in the second half of 2026. The company is also exploring new go-to-market models in Asia-Pacific, strengthening market penetration in Japan, and refining strategy in China in anticipation of volume-based procurement impacts, while maintaining disciplined capital allocation focused on debt reduction and future shareholder returns as performance improves.
| Metric | Target | Period |
|---|---|---|
| Net sales | $3.5 billion–$3.6 billion | FY2026 |
| Adjusted EPS | $1.40–$1.50 | FY2026 |
Net sales (FY2026): “For 2026, we expect net sales to be in the range of $3.5 billion-$3.6 billion, reflecting a -3% to -1% operational growth.”
Adjusted EPS (FY2026): “We expect adjusted earnings per share to be in the range of $1.40-$1.50, reflecting our accelerated investments in innovation, clinical education, Wellspect market penetration, and commercial investments to drive sustained profitable growth globally as we move forward.”
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call, Q2 FY2025 Earnings Call, Q1 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 3.7B | 3.7B | 3.8B | 4.0B | 3.9B | 4.2B |
| Net Income | -628M | -598M | -910M | -132M | -950M | 411M |
| EPS | $-3.15 | $-3.00 | $-4.48 | $-0.62 | $-4.41 | $1.87 |
| Free Cash Flow | 104M | 104M | 281M | 228M | 368M | 515M |
| ROIC | -12.2% | -17.4% | -21.1% | -2.5% | -15.1% | 6.7% |
| Gross Margin | 48.9% | 50.0% | 51.6% | 52.6% | 54.2% | 55.5% |
| Debt/Equity | 1.70 | 2.10 | 1.04 | 0.66 | 0.52 | 0.46 |
| Dividends/Share | $0.64 | $0.64 | $0.64 | $0.56 | $0.50 | $0.43 |
| Operating Income | -520M | -422M | -879M | -85M | -937M | 608M |
| Operating Margin | -14.1% | -11.5% | -23.2% | -2.1% | -23.9% | 14.4% |
| ROE | -47.6% | -36.5% | -34.8% | -3.7% | -21.6% | 8.3% |
| Shares Outstanding | 200M | 199M | 203M | 213M | 215M | 220M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 2.9B | 2.7B | 3.7B | 4.0B | 4.0B | 4.0B | 3.3B | 4.2B | 3.9B | 4.0B | 3.8B | 3.7B | 3.7B |
| Gross Margin | 54.7% | 56.7% | 53.4% | 54.8% | 51.9% | 53.8% | 49.6% | 55.5% | 54.2% | 52.6% | 51.6% | 50.0% | 48.9% |
| R&D | 81M | 75M | 129M | 152M | 161M | 143M | 123M | 171M | 174M | 184M | 165M | 150M | 158M |
| SG&A | 1.1B | 1.1B | 1.5B | 1.7B | 1.7B | 1.6B | 1.3B | 1.6B | 1.6B | 1.6B | 1.6B | 1.4B | 1.4B |
| EBIT | 446M | 375M | 455M | -1.6B | -958M | 353M | -2.0M | 608M | -937M | -85M | -879M | -422M | -520M |
| Op. Margin | 15.2% | 14.0% | 12.1% | -39.1% | -24.0% | 8.8% | -0.1% | 14.4% | -23.9% | -2.1% | -23.2% | -11.5% | -14.1% |
| Net Income | 323M | 251M | 430M | -1.6B | -1.0B | 256M | -73M | 411M | -950M | -132M | -910M | -598M | -628M |
| Net Margin | 11.0% | 9.4% | 11.5% | -38.8% | -25.4% | 6.4% | -2.2% | 9.7% | -24.2% | -3.3% | -24.0% | -16.3% | -17.1% |
| Non-Recurring | 15M | 61M | 18M | 1.7B | 1.1B | 32M | 233M | 31M | 1.2B | 358M | 807M | 549M | 82M |
| Returns on Capital | |||||||||||||
| ROIC | 9.1% | 8.3% | 7.2% | -17.4% | -13.6% | 4.2% | -0.0% | 6.7% | -15.1% | -2.5% | -21.1% | -17.4% | -12.2% |
| ROE | 13.3% | 10.8% | 8.2% | -21.0% | -17.2% | 5.0% | -1.5% | 8.3% | -21.6% | -3.7% | -34.8% | -36.5% | -47.6% |
| ROA | 6.6% | 5.6% | 5.4% | -14.1% | -10.6% | 3.0% | -0.8% | 4.4% | -11.3% | -1.8% | -13.9% | -10.7% | -12.0% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 560M | 497M | 563M | 602M | 500M | 639M | 649M | 657M | 517M | 377M | 461M | 235M | 268M |
| Free Cash Flow | 461M | 425M | 438M | 458M | 317M | 516M | 562M | 515M | 368M | 228M | 281M | 104M | 104M |
| Owner Earnings | 406M | 349M | 250M | 237M | 148M | 250M | 268M | 262M | 130M | -12M | 73M | -150M | -115M |
| CapEx | 100M | 72M | 125M | 144M | 183M | 123M | 87M | 142M | 149M | 149M | 180M | 131M | 164M |
| Maint. CapEx | 129M | 123M | 272M | 316M | 331M | 323M | 334M | 347M | 328M | 343M | 349M | 352M | 352M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 129M | 123M | 272M | 316M | 331M | 323M | 334M | 347M | 328M | 343M | 349M | 352M | 352M |
| CapEx/OCF | 17.8% | 14.5% | 22.2% | 24.0% | 36.5% | 19.4% | 13.4% | 21.6% | 28.8% | 39.5% | 39.0% | 55.7% | 61.2% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 37M | 40M | 65M | 78M | 79M | 81M | 88M | 92M | 104M | 116M | 126M | 128M | 128M |
| Dividend Yield | 0.6% | 0.6% | 0.6% | 0.6% | 0.9% | 0.8% | 1.0% | 0.8% | 1.3% | 1.6% | 2.4% | 4.5% | 4.9% |
| Share Buybacks | 163M | 113M | 814M | 401M | 250M | 260M | 140M | 200M | 150M | 300M | 250M | 0 | 0 |
| Buyback Yield | 2.4% | 1.5% | 7.3% | 3.0% | 3.4% | 2.3% | 1.4% | 1.8% | 2.5% | 4.3% | 6.8% | N/A | 0.0% |
| Stock-Based Comp | 25M | 26M | 41M | 48M | 21M | 66M | 47M | 48M | 59M | 46M | 39M | 33M | 31M |
| Debt Repayment | 199M | 268M | 878M | 17M | 9.0M | 251M | 701M | 297M | 2.0M | 7.0M | 88M | 147M | 147M |
| Balance Sheet | |||||||||||||
| Net Debt | 1.4B | 863M | 1.1B | 1.3B | 1.3B | 1.1B | 2.0B | 2.0B | 1.6B | 1.8B | 1.8B | 2.5B | 2.0B |
| Cash & Equiv. | 152M | 285M | 384M | 321M | 310M | 405M | 438M | 339M | 365M | 334M | 272M | 326M | 190M |
| Long-Term Debt | 1.2B | 1.1B | 1.5B | 1.6B | 1.6B | 1.4B | 2.0B | 1.9B | 1.8B | 1.8B | 1.6B | 2.0B | 2.0B |
| Debt/Equity | 0.66 | 0.49 | 0.18 | 0.25 | 0.32 | 0.30 | 0.50 | 0.46 | 0.52 | 0.66 | 1.04 | 2.10 | 1.70 |
| Interest Coverage | 9.5 | 6.7 | 12.7 | -40.8 | -25.9 | 11.8 | -0.0 | 10.0 | -14.4 | -1.0 | -12.7 | -4.8 | -4.8 |
| Equity | 2.3B | 2.3B | 8.1B | 6.6B | 5.1B | 5.1B | 4.9B | 5.0B | 3.8B | 3.3B | 1.9B | 1.3B | 1.3B |
| Total Assets | 4.6B | 4.4B | 11.6B | 10.4B | 8.7B | 8.6B | 9.3B | 9.2B | 7.6B | 7.4B | 5.8B | 5.4B | 5.2B |
| Total Liabilities | 2.3B | 2.1B | 3.4B | 3.7B | 3.6B | 3.5B | 4.4B | 4.2B | 3.8B | 4.1B | 3.8B | 4.1B | 3.9B |
| Intangibles | 671M | 601M | 3.0B | 2.8B | 2.4B | 2.2B | 2.5B | 2.3B | 1.9B | 1.7B | 1.2B | 974M | 924M |
| Retained Earnings | 3.4B | 3.6B | 3.9B | 2.3B | 1.2B | 1.4B | 1.2B | 1.5B | 456M | 205M | -835M | -1.6B | -1.6B |
| Working Capital | 554M | 721M | 976M | 1.0B | 875M | 1.0B | 426M | 591M | 723M | 548M | 157M | 680M | 638M |
| Current Assets | 1.2B | 1.2B | 1.7B | 2.0B | 1.9B | 2.0B | 1.8B | 1.9B | 1.9B | 2.0B | 1.7B | 2.0B | 1.8B |
| Current Liabilities | 653M | 476M | 768M | 955M | 1.0B | 995M | 1.4B | 1.3B | 1.2B | 1.4B | 1.6B | 1.3B | 1.2B |
| Per Share Data | |||||||||||||
| EPS | 2.24 | 1.76 | 1.94 | -6.76 | -4.51 | 1.14 | -0.33 | 1.87 | -4.41 | -0.62 | -4.48 | -3.00 | -3.15 |
| Owner EPS | 2.82 | 2.44 | 1.13 | 1.04 | 0.66 | 1.11 | 1.21 | 1.19 | 0.60 | -0.06 | 0.36 | -0.75 | -0.57 |
| Book Value | 16.10 | 16.38 | 36.62 | 28.86 | 22.84 | 22.68 | 22.30 | 22.73 | 17.69 | 15.47 | 9.56 | 6.72 | 6.58 |
| Cash Flow/Share | 3.89 | 3.48 | 2.54 | 2.63 | 2.23 | 2.85 | 2.93 | 2.99 | 2.40 | 1.77 | 2.27 | 1.18 | -1.38 |
| Dividends/Share | 0.27 | 0.29 | 0.31 | 0.35 | 0.35 | 0.38 | 0.40 | 0.43 | 0.50 | 0.56 | 0.64 | 0.64 | 0.64 |
| Shares Out. | 144.2M | 142.7M | 221.6M | 229.3M | 224.2M | 224.6M | 221.2M | 219.8M | 215.4M | 212.9M | 203.1M | 199.3M | 200.3M |
| Valuation | |||||||||||||
| P/E Ratio | 20.7 | 30.1 | 26.0 | N/A | N/A | 43.1 | N/A | 27.0 | N/A | N/A | N/A | N/A | -4.1 |
| P/FCF | 14.5 | 17.8 | 25.5 | 29.1 | 23.1 | 21.9 | 18.4 | 21.5 | 16.5 | 30.9 | 13.1 | 22.1 | 24.9 |
| EV/EBIT | 17.4 | 21.7 | 26.3 | N/A | N/A | 33.1 | N/A | 20.9 | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 2.9 | 3.2 | 1.4 | 2.0 | 1.4 | 2.2 | 2.1 | 2.2 | 1.6 | 2.1 | 1.9 | 1.7 | 2.0 |
| Price/Sales | 2.0 | 2.5 | 3.1 | 3.1 | 2.3 | 2.6 | 2.8 | 2.8 | 2.0 | 1.8 | 1.4 | 0.8 | 0.7 |
| FCF Yield | 6.9% | 5.6% | 3.9% | 3.4% | 4.3% | 4.6% | 5.4% | 4.6% | 6.1% | 3.2% | 7.7% | 4.5% | 4.0% |
| Market Cap | 6.7B | 7.6B | 11.2B | 13.3B | 7.3B | 11.3B | 10.4B | 11.1B | 6.1B | 7.0B | 3.7B | 2.3B | 2.6B |
| Avg. Price | 40.83 | 46.49 | 52.22 | 53.59 | 40.35 | 45.71 | 41.59 | 53.92 | 35.91 | 33.57 | 25.65 | 14.27 | 12.93 |
| Year-End Price | 46.29 | 52.90 | 50.52 | 58.04 | 32.69 | 50.43 | 46.85 | 50.45 | 28.23 | 33.07 | 18.06 | 11.52 | 12.93 |
DENTSPLY SIRONA Inc. passes 3 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 24.8x vs a median of 22.0x. The company's 5-year average gross margin is 52.8%. Total shareholder yield (dividends) is 4.9%. At current prices, the estimated annualized return to fair value is -13.5%.
DENTSPLY SIRONA Inc. (XRAY) has a debt-to-equity ratio of 2.10. This indicates higher leverage, which may increase financial risk.
DENTSPLY SIRONA Inc. (XRAY) reported earnings per share (EPS) of $-3.00 in its most recent fiscal year.
DENTSPLY SIRONA Inc. (XRAY) has a return on equity (ROE) of -36.5%. A negative ROE may indicate losses or negative equity.
DENTSPLY SIRONA Inc. (XRAY) has a 5-year average gross margin of 52.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for DENTSPLY SIRONA Inc. (XRAY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
DENTSPLY SIRONA Inc. (XRAY) has a book value per share of $6.72, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management is executing a multi-year Return-to-Growth action plan focused on improving speed, accountability, and customer-centricity, with early momentum evident in commercial restructuring, clinical education expansion, and sales force training. The company is pursuing operational efficiencies through manufacturing and distribution network consolidation, standardized packaging, and advanced planning capabilities to unlock approximately $120 million annually in cost savings to be reinvested in innovation, clinical education, and commercial investments. Management expects more material benefits from these initiatives to emerge in the second half of 2026 and into 2027 and 2028, with positive sequential sales momentum anticipated in the second half of 2026. The company is also exploring new go-to-market models in Asia-Pacific, strengthening market penetration in Japan, and refining strategy in China in anticipation of volume-based procurement impacts, while maintaining disciplined capital allocation focused on debt reduction and future shareholder returns as performance improves.
Based on recent SEC filings and earnings calls, DENTSPLY SIRONA Inc. (XRAY) has provided the following forward guidance: Net sales: $3.5 billion–$3.6 billion (FY2026); Adjusted EPS: $1.40–$1.50 (FY2026).